Volume 7.05 | Feb 9

Pancreatic Cell News 7.05 February 9, 2016
Pancreatic Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PACN on Twitter
 
TOP STORY
Device Hits Pancreatic Tumors Hard With Toxic Four-Drug Cocktail, Sparing the Body
Researchers revealed that an implantable device can deliver a particularly toxic cocktail of drugs directly to pancreatic tumors to stunt their growth or in some cases, shrink them – all while showing signs that the rest of the body would be spared toxic side effects. [Press release from the University of North Carolina at Chapel Hill discussing online prepublication in Proceedings of the National Academy of Sciences] Press Release | Abstract
Differentiation Doesn't Have to be Difficult - Get Easy, Standardized hPSC Differentiation
 
PUBLICATIONS (Ranked by impact factor of the journal)
DIABETES & PANCREATITIS

Myotubes Derived from Human-Induced Pluripotent Stem Cells Mirror In Vivo Insulin Resistance
Scientists have created a novel cellular model of human muscle insulin resistance by differentiating induced pluripotent stem cells from individuals with mutations in the insulin receptor into functional myotubes and characterizing their response to insulin in comparison with controls. [Proc Natl Acad Sci USA] Abstract | Full Article

Exosome-Like Vesicles Released from Lipid-Induced Insulin-Resistant Muscles Modulate Gene Expression and Proliferation of Beta Recipient Cells in Mice
Scientists investigated whether skeletal muscle-released exosome-like vesicles can be taken up by pancreatic beta cells and can deliver functional cargoes. [Diabetologia] Abstract

Peribiliary Glands as a Niche of Extra-Pancreatic Precursors Yielding Insulin-Producing Cells in Experimental and Human Diabetes
The authors evaluated, in experimental and human diabetes, proliferation of cells in peribiliary glands and differentiation of the biliary tree stem/progenitor cells towards insulin-producing cells. [Stem Cells] Abstract

Redifferentiation of Expanded Human Islet β Cells by Inhibition of ARX
Investigators aimed to improve redifferentiation efficiency by affecting the balance of islet progenitor-cell transcription factors activated by Redifferentiation Cocktail (RC) treatment. Specifically, RC treatment induced the transcription factors PAX4 and ARX, which play key roles in directing pancreas endocrine progenitor cells into the β/δ or α/PP developmental pathways, respectively. [Sci Rep] Full Article

Bif-1 Deficiency Impairs Lipid Homeostasis and Causes Obesity Accompanied by Insulin Resistance
Researchers showed that Bif-1 deficiency promotes the expansion of adipose tissue mass without altering food intake or physical activities. [Sci Rep] Full Article

Glucose Intolerance Develops Prior to Increased Adiposity and Accelerated Cessation of Estrous Cyclicity in Female Growth-Restricted Rats
Scientists tested the hypothesis that intrauterine growth restriction programs early reproductive aging and impaired glucose homeostasis in female rats. [Pediatr Res] Abstract

PANCREATIC CANCER

CYP3A5 Mediates Basal and Acquired Therapy Resistance in Different Subtypes of Pancreatic Ductal Adenocarcinoma
The authors present patient-derived models representing the full spectrum of previously identified quasi-mesenchymal, classical and exocrine-like pancreatic ductal adenocarcinoma subtypes, and identify two markers—HNF1A and KRT81—that enable stratification of tumors into different subtypes by using immunohistochemistry. [Nat Med] Abstract

EZH2 Promotes Cell Migration and Invasion but Does Not Alter Cell Proliferation by Suppressing E-Cadherin, Partly through Association with MALAT-1 in Pancreatic Cancer.
Researchers investigated the effects of aberrantly expressed enhancer of zeste homolog 2 (EZH2) on pancreatic cancer. They found that EZH2 expression is up-regulated in pancreatic cancer tissues and positively correlated with lymph node metastasis and advanced clinical stage in pancreatic cancer patients. [Oncotarget] Full Article

Smad4-Dependent Suppressor Pituitary Homeobox 2 Promotes PPP2R2A-Mediated Inhibition of Akt Pathway in Pancreatic Cancer
Scientists performed gene expression profiling of human pancreatic ductal adenocarcinoma (PDAC) tissues and identified pituitary homeobox 2 (Pitx2) as a promising candidate. Pitx2 expression was decreased from 2.6- to 19-fold in human PDAC tissues from microarray units. [Oncotarget] Full Article

ALDOA Functions as an Oncogene in the Highly Metastatic Pancreatic Cancer
Investigators analyzed gene expression signatures in highly malignant patients. Multiple differentially expressed genes were identified, many of which were closely related with cancer metabolic changes. [Cancer Lett] Abstract

Learn More: STEMdiff™ Pancreatic Progenitor Kit
 
REVIEWS
Current Standards and New Innovative Approaches for Treatment of Pancreatic Cancer
Pancreatic adenocarcinoma remains a devastating disease with a five-year survival rate not exceeding six percent. This article reviews the state-of-the-art in the management of this disease and the new innovative approaches that may help to accelerate progress in treating its victims. [Eur J Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
 
INDUSTRY NEWS
Scripps Florida Scientists Win $1.2 Million to Study New Strategies for Treating Obesity, Diabetes, Cardiovascular Disease and Muscle Decline
Scientists from the Florida campus of The Scripps Research Institute have been awarded nearly $1.2 million from the National Institutes of Health to create a series of drug candidates that advance more effective treatments for a range of conditions, including obesity, type-2 diabetes, cardiovascular disease and muscle atrophy. [The Scripps Research Institute] Press Release

Immunovia Announces Collaboration with Mount Sinai Health System to Validate Early Detection Blood Test for Pancreatic Cancer in a Prospective Clinical Study
Immunovia AB announced that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the United States and Europe, starting second half of 2016. [Immunovia AB] Press Release

Another £1 Million for Research Projects Sees PCRF Research Spend Hit £8 Million!
Pancreatic Cancer Research Fund (PCRF) has funded six new research projects with a total of £1 million – bringing the charity’s support for research into the United Kingdom’s most lethal cancer to over £8 million. [Pancreatic Cancer Research Fund] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine.
Request a free wallchart from Nature.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Tumor Microenvironment and Signaling
April 3-6, 2016
Heidelberg, Germany

Visit our events page to see a complete list of events in the pancreatic cell community.
 
JOB OPPORTUNITIES
NEW Faculty Position – Metabolic Disease Research (Lewis Katz School of Medicine)

NEW Postdoctoral Fellowship – Diabetes (Danish Diabetes Academy)

Research Associate – Therapeutic Strategies in Pancreatic Adenocarcinoma (University of Cambridge)

Post-Doc Fellowship – Glucose Metabolism (Joslin Diabetes Center)

Research Associate – Cancer Pharmacology in Pancreatic Adenocarcinoma (University of Cambridge)

Post-Doc Fellowship – Computational Analysis Pancreas (Karolinska Institutet)

Post-Doc Researcher – Drug Discovery in Cancer/Diabetes (D. E. Shaw Research)

Post-Doc Fellowship – Diabetes Research (Sanford Research/University of South Dakota)

Faculty Position – Biomedical Metabolomics & Metabolism (University of Ottawa)

Visiting Scientist – Diabetes (Danish Diabetes Academy)

Post-Doc Researcher – Type 1 Diabetes (University of Turku)

MD/PhD Researcher – Biomedical Sciences (Hannover Medical School)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us